Centering their discussion on cornerstone therapies, expert hematologist-oncologists consider the treatment paradigms of essential thrombocythemia and polycythemia vera. Rami Komrokji, M.D.: Once we ...
A recent study identified trends in blood counts, but did not find statistically significant associations between achieving hematological remission and clinical outcomes in polycythemia vera (PV) or ...
This trial looked at a drug called ruxolitinib to treat high risk polycythaemia vera (PV) and high risk essential thrombocythaemia (ET). This trial closed in 2016. These results published in 2017 are ...
Health-related quality of life (HRQoL) of bosutinib (SKI-606) in imatinib-resistant (IM-R) or imatinib-intolerant (IM-I) chronic phase chronic myeloid leukemia (CP CML). This is an ASCO Meeting ...
The MPN Research Foundation, a respected and influential member of the myeloproliferative neoplasms landscape, has two abstracts accepted for presentation at the 67th American Society of Hematology ...
Overexpression of the Polycythemia Rubra Vera-1 Gene in Essential Thrombocythemia. If you have the appropriate software installed, you can download article citation data to the citation manager of ...
Nona Baker, who was first diagnosed with a blood cancer in 1991, shares her experience with polycythemia vera. Nona Baker, ...
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood ...
LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by GlaxoSmithKline for OJJAARA™ (momelotinib). OJJAARA is a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback